Patents by Inventor Keith Limbach
Keith Limbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210260176Abstract: The present invention provides methods and compositions for immunizing a subject against malaria.Type: ApplicationFiled: March 30, 2018Publication date: August 26, 2021Applicant: United States of America as Represented by the Secretary of the NavyInventors: Joao Carlos Aguiar, Keith Limbach, Emily Smith
-
Publication number: 20170219560Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: April 10, 2017Publication date: August 3, 2017Applicant: United States of America as Represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, Richter C. King, Denise L. Doolan, Joao C. Aguair, Daniel J. Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Patent number: 9694062Abstract: The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation.Type: GrantFiled: March 19, 2014Date of Patent: July 4, 2017Assignee: The United States of America as Represented by the Secretary of the NavyInventors: Joao Aguiar, Keith Limbach, Martha Sedegah, Thomas Richie
-
Patent number: 9651543Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: GrantFiled: April 19, 2013Date of Patent: May 16, 2017Assignee: The United States of America as Represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Publication number: 20170082607Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: April 19, 2013Publication date: March 23, 2017Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Patent number: 9254316Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.Type: GrantFiled: May 9, 2013Date of Patent: February 9, 2016Assignee: The United States of America as represented by the Secretary of the NavyInventors: Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louise Doolan
-
Publication number: 20150265690Abstract: The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation.Type: ApplicationFiled: March 19, 2014Publication date: September 24, 2015Inventors: JOAO AGUIAR, KEITH LIMBACH, MARTHA SEDEGAH, THOMAS RICHIE
-
Publication number: 20140335128Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.Type: ApplicationFiled: May 9, 2013Publication date: November 13, 2014Inventors: Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louise Doolan
-
Publication number: 20140314809Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: April 19, 2013Publication date: October 23, 2014Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Patent number: 8450055Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: GrantFiled: August 25, 2006Date of Patent: May 28, 2013Assignee: The United States of America as Represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Publication number: 20110104195Abstract: The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation.Type: ApplicationFiled: November 3, 2010Publication date: May 5, 2011Inventors: Joao Aguiar, Keith Limbach, Martha Sedagah, Thomas Richie
-
Publication number: 20100278870Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.Type: ApplicationFiled: January 9, 2008Publication date: November 4, 2010Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louise Doolan
-
Publication number: 20100222234Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.Type: ApplicationFiled: August 25, 2006Publication date: September 2, 2010Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
-
Publication number: 20090148477Abstract: The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.Type: ApplicationFiled: August 31, 2006Publication date: June 11, 2009Applicant: GENVEC, INC.Inventors: Joseph T. Bruder, Imre Kovesdi, C. Richter King, Duncan L. McVey, Damodar R. Ettyreddy, Denise Louis Doolan, Daniel John Carucci, Keith Limbach
-
Publication number: 20080248060Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.Type: ApplicationFiled: January 9, 2008Publication date: October 9, 2008Applicants: GENVEC, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARInventors: Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louis Doolan